Orthocell’s entry to to the Canadian market with the first sales of Striate+ has been reported in The Australian in the article “Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada”.

The article outlines the swift transition from approval to revenue generation in this new market, and points to Striate+’s strong market acceptance and potential.

Here’s an excerpt:

“Strong sales traction in the existing markets has been driven by BioHorizons’ comprehensive marketing and medical education program, which has effectively informed clinicians about the benefits of Striate+.

This success is further supported by Striate+’s outstanding 98.6% success rate in the post-market clinical study.

Consequently, the product’s high-quality performance is motivating BioHorizons to pursue expansion into other large, attractive markets where they have established accounts and distribution networks.”

Click here to read the article. 

Following the announcement that Orthocell is accelerating its global market expansion of Striate+™ and Remplir™, Managing Director Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s seven regulatory applications in progress or planned, targeting approval in significant markets.

Paul spoke of the positive feedback from clinicians on Orthocell’s innovative regenerative medicine products and plans to capture a meaningful share of the global market as part of the Company’s growth strategy.

“Orthocell has always focused on providing solutions for clinicians. When you combine those that are available to us, from both our dental bone product and our nerve product, we’re talking about $3 billion a year in addressable markets. We’re very confident, given the outstanding uptake that we’ve seen for both Striate+ and Remplir, that we can drive towards a 20% market share of that market. And we think that we can do that with our partners, in conjunction with the excellent product and education that we provide to surgeons internationally.”